Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) have received an average rating of “Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $51.40.

ABCL has been the subject of a number of research reports. Berenberg Bank initiated coverage on shares of AbCellera Biologics in a research note on Tuesday, January 5th. They set a “buy” rating and a $53.00 target price for the company. ValuEngine cut shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research note on Thursday, January 7th. BMO Capital Markets began coverage on shares of AbCellera Biologics in a research note on Tuesday, January 5th. They set an “outperform” rating and a $48.00 target price for the company. Credit Suisse Group began coverage on shares of AbCellera Biologics in a research report on Tuesday, January 5th. They set an “outperform” rating and a $52.00 price target on the stock. Finally, SVB Leerink began coverage on shares of AbCellera Biologics in a research report on Tuesday, January 5th. They set an “outperform” rating and a $45.00 price target on the stock.

ABCL stock traded up $3.93 during trading hours on Friday, reaching $43.88. The stock had a trading volume of 1,911,501 shares, compared to its average volume of 1,487,875. AbCellera Biologics has a fifty-two week low of $36.27 and a fifty-two week high of $71.91.

About AbCellera Biologics

There is no company description available for AbCellera Biologics Inc

See Also: How To Calculate Debt-to-Equity Ratio

Analyst Recommendations for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.